Lonza Biologics

Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
AAV Lentiviral Cell Therapy mRNA
1 confirmed programs · 1 sponsors · Last scored 2026-03-15
84.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (1) ○ SEC Filings ✓ Press (20)

Quick Facts: Lonza Biologics

Signal Score
84.0/100 (as of 2026-03-15)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
Modalities
AAV, Lentiviral, Cell Therapy, mRNA
Active CGT Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 87.8
1 active programs across 1 sponsors
Modalities: mRNA, Cell Therapy, Lentiviral, AAV
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: mRNA, Cell Therapy, Lentiviral, AAV
Programs 1
Sponsors1
ModalitiesAAV, Lentiviral, Cell Therapy, mRNA
1 active programs across 1 sponsors
Modalities: mRNA, Cell Therapy, Lentiviral, AAV
Source: ClinicalTrials.gov facility matching
NCT04809766 Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment... PHASE1 Terminated
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 75.0
Multi-site operations (4 CGT sites)
Broad modality coverage (4 modalities)
Sites: Houston, TX, Portsmouth, NH, Geleen, NL, Basel, CH
Source: SEC EDGAR, press monitoring, company profiles
4 CGT manufacturing sites
StatusLimited
Multi-site operations (4 CGT sites)
Broad modality coverage (4 modalities)
Sites: Houston, TX, Portsmouth, NH, Geleen, NL, Basel, CH
Recent Press20 articles
Multi-site operations (4 CGT sites)
Broad modality coverage (4 modalities)

Clinical Activity 1 studies

NCT04809766 Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic... PHASE1 Terminated
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026

Recent News 20 articles

general 2026-03-20
Lonza Group AG stock under pressure amid Swiss trade surplus data and CDMO transformation momentum - AD HOC NEWS
Lonza Group AG stock under pressure amid Swiss trade surplus data and CDMO transformation momentum  AD HOC NEWS
Source →
regulatory 2026-03-16
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership - AD HOC NEWS
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership  AD HOC NEWS
Source →
general 2026-03-16
Lonza becomes pure-play CDMO - Speciality Chemicals Magazine
Lonza becomes pure-play CDMO  Speciality Chemicals Magazine
Source →
regulatory 2026-03-16
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership - AD HOC NEWS
Lonza Group AG stock: Global expansion accelerates with India hub and fermentation market leadership  AD HOC NEWS
Source →
general 2026-03-15
Lonza Group AG Stock (ISIN: CH0013841017) Holds Steady Amid Biopharma Sector Volatility - AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Holds Steady Amid Biopharma Sector Volatility  AD HOC NEWS
Source →
regulatory 2026-03-14
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing - AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing  AD HOC NEWS
Source →
regulatory 2026-03-14
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing - AD HOC NEWS
Lonza Group AG Stock Faces Headwinds Amid Sector Repricing  AD HOC NEWS
Source →
general 2026-03-13
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts - AD HOC NEWS
Lonza Group AG Stock (ISIN: CH0013841017) Faces Biopharma Pressures Amid Sector Shifts  AD HOC NEWS
Source →
ma 2026-03-12
Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn - Nutraceutical Business Review
Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn  Nutraceutical Business Review
Source →
general 2026-03-11
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia - GEN - Genetic Engineering and Biotechnology News
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia  Genetic Engineering and Biotechnology News
Source →
regulatory 2026-03-10
Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO - Indian Pharma Post
Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO  Indian Pharma Post
Source →
general 2026-03-10
Viral Vector Manufacturing Market Set to Witness Rapid Growth - openPR.com
Viral Vector Manufacturing Market Set to Witness Rapid Growth  openPR.com
Source →
ma 2026-03-10
Lonza Divests Capsules & Health Ingredients Business for $3 Billion - CHEManager
Lonza Divests Capsules & Health Ingredients Business for $3 Billion  CHEManager
Source →
general 2026-03-09
Lonza, Genetix Bio Extend Commercial Mfg. Pact for ZYNTEGLO - Contract Pharma
Lonza, Genetix Bio Extend Commercial Mfg. Pact for ZYNTEGLO  Contract Pharma
Source →
general 2026-03-09
Lonza Group - Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For Zynteglo - TradingView
Lonza Group - Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For Zynteglo  TradingView
Source →
general 2026-03-09
Lonza Expands Genetix ZYNTEGLO Manufacturing as Gene Therapy Demand Surges - TipRanks
Lonza Expands Genetix ZYNTEGLO Manufacturing as Gene Therapy Demand Surges  TipRanks
Source →
general 2026-03-09
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO - boerse.de
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO  boerse.de
Source →
general 2026-03-09
Lonza Sells Its Capsules Unit To Refocus On CDMO Growth - Finimize
Lonza Sells Its Capsules Unit To Refocus On CDMO Growth  Finimize
Source →
general 2026-03-09
Switzerland: Lonza completing transformation to pure-play CDMO with divestment of Capsules & Health Ingredients - Investors in Healthcare
Switzerland: Lonza completing transformation to pure-play CDMO with divestment of Capsules & Health Ingredients  Investors in Healthcare
Source →
general 2026-03-09
Lonza Sells Its Capsules Unit And Doubles Down On CDMO - Finimize
Lonza Sells Its Capsules Unit And Doubles Down On CDMO  Finimize
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Cell Therapy CDMOs → mRNA CDMOs →